Can you take Mecamylamine with Primatene?

The ePHEDrine in Primatene has a moderate potential interaction with Benign Prostatic Hyperplasia.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

Mecamylamine has a moderate potential interaction with Bleeding Disorder.

The action of mecamylamine may be potentiated by excessive heat, fever, infection, bleeding, vigorous exercise and salt depletion, as a result of diminished intake or increase excretion due to diarrhea, vomiting, excessive sweating or diuretics.

The ePHEDrine in Primatene has a major potential interaction with Cardiovascular Conditions and Disorders.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Mecamylamine has a major potential interaction with Cerebral Vascular Disorder.

Cerebrovascular ischemia can occur as a result of marked hypotension during mecamylamine therapy. Therapy with mecamylamine should be administered cautiously in patients with or a history of cerebrovascular disorders.

The ePHEDrine in Primatene has a major potential interaction with Cerebrovascular Insufficiency.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Mecamylamine has a moderate potential interaction with Dehydration.

The action of mecamylamine may be potentiated by excessive heat, fever, infection, bleeding, vigorous exercise and salt depletion, as a result of diminished intake or increase excretion due to diarrhea, vomiting, excessive sweating or diuretics.

The ePHEDrine in Primatene has a moderate potential interaction with Diabetes Mellitus.

Ephedrine may produce slight increases in blood glucose concentrations. Therapy with ephedrine should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of ephedrine are not exceeded.

The ePHEDrine in Primatene has a moderate potential interaction with Diabetes Mellitus.

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

Mecamylamine has a moderate potential interaction with Diarrhea.

The action of mecamylamine may be potentiated by excessive heat, fever, infection, bleeding, vigorous exercise and salt depletion, as a result of diminished intake or increase excretion due to diarrhea, vomiting, excessive sweating or diuretics.

Mecamylamine has a moderate potential interaction with Fever.

The action of mecamylamine may be potentiated by excessive heat, fever, infection, bleeding, vigorous exercise and salt depletion, as a result of diminished intake or increase excretion due to diarrhea, vomiting, excessive sweating or diuretics.

Mecamylamine has a major potential interaction with Glaucoma/Intraocular Hypertension.

The use of mecamylamine is contraindicated in patients with glaucoma.

The ePHEDrine in Primatene has a major potential interaction with Hyperthyroidism.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Mecamylamine has a major potential interaction with Ischemic Heart Disease.

The use of mecamylamine is contraindicated in patients with coronary artery disease or insufficiency or a recent myocardial infarction. Mecamylamine blocks sympathetic ganglia causing vasodilation, increased peripheral blood flow, and decreased blood pressure.

Mecamylamine has a major potential interaction with Myoneural Disorder.

CNS toxicity such as tremors, choreiform movements, altered mental status, and convulsions have occurred rarely. Patients with cerebral or renal impairment are at increased risk for mecamylamine- associated CNS toxicity. Therapy with mecamylamine should be administered cautiously in patients with or predisposition to neurological disorders. Clinical monitoring of neurological status and renal function (as indicated) is recommended.

The ePHEDrine in Primatene has a major potential interaction with Pheochromocytoma.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The ePHEDrine in Primatene has a moderate potential interaction with Prostate Tumor, Benign.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

Mecamylamine has a major potential interaction with Psychosis.

CNS toxicity such as tremors, choreiform movements, altered mental status, and convulsions have occurred rarely. Patients with cerebral or renal impairment are at increased risk for mecamylamine- associated CNS toxicity. Therapy with mecamylamine should be administered cautiously in patients with or predisposition to neurological disorders. Clinical monitoring of neurological status and renal function (as indicated) is recommended.

Mecamylamine has a major potential interaction with Renal Dysfunction.

Mecamylamine is primarily eliminated by the kidney, and it should be given with great discretion, if at all, when renal insufficiency is manifested by a rising or elevated BUN. This drug is contraindicated in uremia.

Mecamylamine has a major potential interaction with Urinary Retention.

The parasympathetic blocking activity of mecamylamine can cause bladder atony and urinary retention. Therapy with mecamylamine should be administered cautiously in patients with urinary retention, prostatic hypertrophy, bladder neck obstruction, or urethral stricture.

The ePHEDrine in Primatene has a moderate potential interaction with Urinary Tract Obstruction.

Sympathomimetic agents such as ephedrine have the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with ephedrine should be administered cautiously in patients with difficulty for urination due to hypertrophy or neoplasm of the prostate. It is important that the recommended dosages are not exceeded.

Mecamylamine has a moderate potential interaction with Vomiting.

The action of mecamylamine may be potentiated by excessive heat, fever, infection, bleeding, vigorous exercise and salt depletion, as a result of diminished intake or increase excretion due to diarrhea, vomiting, excessive sweating or diuretics.